Showing 1 - 13 results of 13 for search 'Karen T Liby', query time: 0.05s Refine Results
  1. 1
    Synthetic Triterpenoids Can Protect against Toxicity without Reducing the Efficacy of Treatment with Carboplatin and Paclitaxel in Experimental Lung Cancer

    Synthetic Triterpenoids Can Protect against Toxicity without Reducing the Efficacy of Treatment with Carboplatin and Paclitaxel in Experimental Lung Cancer by Karen T. Liby

    Published 2014-01-01
    Get full text
    Article
  2. 2
    <i>KEAP1</i>-Mutant Lung Cancers Weaken Anti-Tumor Immunity and Promote an M2-like Macrophage Phenotype

    <i>KEAP1</i>-Mutant Lung Cancers Weaken Anti-Tumor Immunity and Promote an M2-like Macrophage Phenotype by Christopher J. Occhiuto, Karen T. Liby

    Published 2024-03-01
    Get full text
    Article
  3. 3
    The Novel RXR Agonist MSU-42011 Differentially Regulates Gene Expression in Mammary Tumors of MMTV-Neu Mice

    The Novel RXR Agonist MSU-42011 Differentially Regulates Gene Expression in Mammary Tumors of MMTV-Neu Mice by Lyndsey A. Reich, Ana S. Leal, Edmund Ellsworth, Karen T. Liby

    Published 2023-02-01
    Get full text
    Article
  4. 4
    The Bromodomain Inhibitor, INCB057643, Targets Both Cancer Cells and the Tumor Microenvironment in Two Preclinical Models of Pancreatic Cancer

    The Bromodomain Inhibitor, INCB057643, Targets Both Cancer Cells and the Tumor Microenvironment in Two Preclinical Models of Pancreatic Cancer by Ana S. Leal, Phillip Liu, Teresa Krieger-Burke, Bruce Ruggeri, Karen T. Liby

    Published 2020-12-01
    Get full text
    Article
  5. 5
    CDDO-Me Redirects Activation of Breast Tumor Associated Macrophages.

    CDDO-Me Redirects Activation of Breast Tumor Associated Macrophages. by Michael S Ball, Emilie P Shipman, Hyunjung Kim, Karen T Liby, Patricia A Pioli

    Published 2016-01-01
    Get full text
    Article
  6. 6
    A synthetic triterpenoid CDDO-Im inhibits tumorsphere formation by regulating stem cell signaling pathways in triple-negative breast cancer.

    A synthetic triterpenoid CDDO-Im inhibits tumorsphere formation by regulating stem cell signaling pathways in triple-negative breast cancer. by Jae Young So, Janice J Lin, Joseph Wahler, Karen T Liby, Michael B Sporn, Nanjoo Suh

    Published 2014-01-01
    Get full text
    Article
  7. 7
    Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice

    Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice by Di Zhang, Bijay Singh, Jessica Moerland, Owen Mitchell, Lizbeth Lockwood, Sarah Carapellucci, Srinivas Sridhar, Karen T. Liby

    Published 2021-01-01
    Get full text
    Article
  8. 8
    The Triterpenoid CDDO-Methyl Ester Redirects Macrophage Polarization and Reduces Lung Tumor Burden in a Nrf2-Dependent Manner

    The Triterpenoid CDDO-Methyl Ester Redirects Macrophage Polarization and Reduces Lung Tumor Burden in a Nrf2-Dependent Manner by Jessica A. Moerland, Ana S. Leal, Beth Lockwood, Elena Y. Demireva, Huirong Xie, Teresa Krieger-Burke, Karen T. Liby

    Published 2023-01-01
    Get full text
    Article
  9. 9
    T Cells and CDDO-Me Attenuate Immunosuppressive Activation of Human Melanoma-Conditioned Macrophages

    T Cells and CDDO-Me Attenuate Immunosuppressive Activation of Human Melanoma-Conditioned Macrophages by Gretel M. Torres, Heetaek Yang, Chanhyuk Park, Paul A. Spezza, Nikhil Khatwani, Rajan Bhandari, Karen T. Liby, Patricia A. Pioli

    Published 2022-02-01
    Get full text
    Article
  10. 10
    The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer

    The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer by Ana S. Leal, Jessica A. Moerland, Di Zhang, Sarah Carapellucci, Beth Lockwood, Teresa Krieger-Burke, Bilal Aleiwi, Edmund Ellsworth, Karen T. Liby

    Published 2021-10-01
    Get full text
    Article
  11. 11
    The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer

    The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer by Jessica A. Moerland, Di Zhang, Lyndsey A. Reich, Sarah Carapellucci, Beth Lockwood, Ana S. Leal, Teresa Krieger-Burke, Bilal Aleiwi, Edmund Ellsworth, Karen T. Liby

    Published 2020-12-01
    Get full text
    Article
  12. 12
    The rexinoid V-125 reduces tumor growth in preclinical models of breast and lung cancer

    The rexinoid V-125 reduces tumor growth in preclinical models of breast and lung cancer by Lyndsey A. Reich, Jessica A. Moerland, Ana S. Leal, Di Zhang, Sarah Carapellucci, Beth Lockwood, Peter W. Jurutka, Pamela A. Marshall, Carl E. Wagner, Karen T. Liby

    Published 2022-01-01
    Get full text
    Article
  13. 13
    Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription.

    Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. by Lichuan Yang, Noel Y Calingasan, Bobby Thomas, Rajnish K Chaturvedi, Mahmoud Kiaei, Elizabeth J Wille, Karen T Liby, Charlotte Williams, Darlene Royce, Renee Risingsong, Eric S Musiek, Jason D Morrow, Michael Sporn, M Flint Beal

    Published 2009-06-01
    Get full text
    Article

Search Tools: